Genmab formalises the challenge against its partner
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
No SOS for Bayer's SOS1
The group goes after a KRAS-related target on which Boehringer recently gave up.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
European radiopharmaceuticals head for the clinic
First-in-human study starts include radioligands from Akiram and Philogen.
